sar425899 glucagon glp-1 dual agonist sanofi Transforming obesity: The advancement of multi-receptor drugs: Cell How glucagon-like peptide 1 receptor

95% CI, -0.02 to 0.03

New analyses involving more than 100,000 patients suggest that users of popular diabetes and weight-loss medications face a lower risk of developing certain cancers and a reduced risk of metastasis.

Counting the days since you had your last poop? Oof

How GLP-1 and GIP pathways work, why dual-action tirzepatide (Mounjaro) differs from GLP-1-only medicines, and what trial averages mean for UK patients.

In this GLP1 capsule, every natural, premium ingredient works together to support optimal overall health

Summary GLP-1 RAs offer a multifaceted therapeutic strategy in PD, targeting both central neurodegenerative processes and peripheral metabolic dysfunction